Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
DRUG: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

Sponsor

Mineralys Therapeutics Inc.